AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05409911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-217622
Description: Tablet for oral administration
Study NCT06047145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: 1 capsule daily for 84 days
Study NCT06047145 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily for 84 days
Study NCT06386783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injection [Precedex]
Description: Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
Study NCT06386783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl HCl
Description: Compare between the efficacy of dexmedetomidine and fentanyl as adjuvants on decreasing the intraoperative peritoneal symptoms such as abdominal discomfort or visceral pain, nausea and vomiting, vagal symptoms like bradycardia and hypotension during appendectomy.
Study NCT05351164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metreleptin
Description: Study drug for injection is supplied in a carton containing 30 vials for reconstitution. Each vial contains 11.3 mg of the study drug as a sterile, white, solid, lyophilized cake or powder to deliver 5 mg/mL of the study drug when reconstituted with 2.2 mL of water for injection (WFI).
Study NCT05492591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α1b
Description: Injecting different doses of the peginterferon α1b into different groups of subjects.
Study NCT05492591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon α1b with valacyclovir
Description: Both valacyclovir tablets and different dose of peginterferon α1b plan to be used in different groups of subjects.
Study NCT05492591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: Valacyclovir is a positive control drug.
Study NCT06060340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: class II furcation defects management using propolis
Description: A full thickness flap will be elevated using muco-periosteal elevator to gain full access to the furcation defect. Then granulomatous tissue will be debrided from the osseous defect and the root surfaces will be carefully scaled and root planed by ultrasonic and hand instruments.~The diagnosis of the class II furcation defect was then confirmed using a Naber's probe.~Propolis preparation:~Pure propolis will then be mixed with saline to give a proper mix/consistency and applied to completely fill the furcation defect.
Study NCT06091098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic CO2
Description: 2% inspired CO2 for 2-4 breaths
Study NCT06091098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic CO2
Description: 2% inspired CO2 for 2-4 breaths
Study NCT06091098 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham CO2
Description: Air
Study NCT06199427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 25mg/kg (days +3, +4) after HSCT from MUD and MRD Cyclophosphamide 50mg/kg (days +3, +4) after HSCT from MMRD
Study NCT06199427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 7 mg/m2 from day +5 after HSCT
Study NCT01562652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposTherapy (All Phases of Step-cycle {APOS} system, APOS-Medical and Sports Technologies Ltd. Herzliya, Israel)
Study NCT04714190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.5 mg/kg IV every 2 weeks
Study NCT04714190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel injection
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study NCT04714190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride Injection
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study NCT04714190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib Mesylate Tablets
Description: Administered according to label, as one option for Physician's Choice (determined before randomization)
Study NCT04824742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PDT + radical surgery
Description: Patients with cholangiocarcinoma will undergo radical surgery after photodynamic therapy
Study NCT04824742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery
Description: Patients with cholangiocarcinoma will only receive radical surgery
Study NCT04728698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVI-MSC
Description: 1 x 10\^6 MSCs/kg or 1.5 x 10\^6 MSCs/kg, depending on CRP level
Study NCT04728698 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent volume of placebo will be administered
Study NCT04668209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silmitasertib
Description: Standard of care / best supportive care in combination with CX-4945 1000 mg administered orally, two times a day.
Study NCT04840589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan
Study NCT04840589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study NCT06456463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp
Description: Tagraxofusp will be administered by intravenous infusion on days 4, 5, and 6 of each 28-day cycle.
Study NCT06456463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as an oral tablet (400 milligrams) daily of each 28-day cycle.
Study NCT06456463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered subcutaneously or by intravenous infusion (75 milligrams/square meter) over 7 days of each 28-day cycle, per institutional guidelines/physician choice.
Study NCT05160480 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Total-body PET imaging
Description: Total-body PET imaging at different timepoints
Study NCT06520514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spesolimab
Description: Spesolimab
Study NCT06520514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab
Study NCT06011603 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prineo dressing
Description: Prineo dressing is a common dressing option used in Joint Arthroplasty surgery. It is an adhesive dressing growing in popularity that is thought to lead to reinforced tension across the wound while also decreasing the skin edge ischemia.
Study NCT05974202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active H7-coil repetitive transcranial magnetic stimulation (rTMS)
Description: A magnetic current created by the device creates an electrical current in the brain to stimulate the medial prefrontal cortex and dorsal anterior cingulate cortex.
Study NCT05974202 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham H7-coil repetitive transcranial magnetic stimulation (rTMS)
Description: A sham coil is in the same helmet as the active coil. The sham coil mimics the sound, scalp sensations, and facial muscle activation caused by the active coil, but does not create an electrical current in the brain.
Study NCT05601726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABD-3001
Description: Each patient will receive a fixed 4 hours-intravenous infusion dose of ABD-3001 once or twice a week.~For SAD : The first dose of the first cohort will receive an estimated infusion dose of 18 mg/m² at Day 1. Subsequent cohorts will be given the following doses: 54 mg/m², 135 mg/m², 270 mg/m², 405 mg/m², 540 mg/m².
Study NCT05601726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABD-3001
Description: For MAD :~Based on all data gathered during the SAD including safety, PK and preliminary efficacy data, up to three doses were selected in accordance with the Safety review Committee (SRC). A dosage optimization analysis was performed at the end of the SAD cohort 6 using population pharmacokinetic modelling to set the optimal frequency of infusion per week for each selected dose to achieve sustained exposition throughout the treatment period. Based on this analysis, the Sponsor, in agreement with the SRC, defined 3 doses regimens that will be set up in parallel, with infusion of ABD-3001 once or twice a week during 3 cycles of 28 days.
Study NCT04842643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGSC 20% infusion
Description: IGSC 20% infusion,
Study NCT06014034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programmed Weaning From Noninvasive Mechanical Ventilation
Description: Programmed withdrawal unit: daily morning review arterial blood gas analysis (since the 2nd, daily morning stop non-invasive ventilation 1 hours, 2 hours, 3 hours, 4 hours after check arterial blood gas analysis), blood gas results suggest respiratory acidosis compensatory period (pH value greater than 7.35) can reduce daily noninvasive ventilation time, namely the noninvasive ventilation use time for 24 hours, 20 hours, the third day 16 hours, the fourth 12 hours, fifth day 8 hours. If ABG indicates still acid decompensation, continue the non-invasive ventilation regimen of the previous day. If noninvasive ventilation failed, invasive mechanical ventilation was performed.
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered by intravenous infusion
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Administered by intravenous infusion
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Administered by intravenous infusion
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Administered by intravenous infusion
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Administered by intravenous infusion
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered by intravenous infusion
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered by intravenous infusion
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered by intravenous infusion
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given orally
Study NCT06435429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally
Study NCT05202860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine
Description: (Gardasil 9 human papilloma vaccine)
Study NCT05202860 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO vaccine
Description: Isotonic saltwater sham vaccine
Study NCT06541847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX-1502
Description: Participants will take an oral dose three times a day (with or without food) for up to 24 cycles (A cycle is defined as 28 days)
Study NCT05976945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting
Description: In Imagery Rescripting patients imagine a different sequence of events matching their needs better than what actually happened in traumatic and other adverse (childhood) experiences.
Study NCT05083442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low Level Laser Therapy
Description: Non-surgical cosmetic treatment which can be used by individuals intending to reduce size of the mid-section
Study NCT05083442 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (placebo)
Description: Use of sham (placebo) option
Study NCT05816551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia Trial
Description: Individuals will be exposed to a controlled hyperthermia trial during Visit 2 of the protocol.
Study NCT05816551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Trial
Description: Individuals will be exposed to a control trial (no hyperthermia) during Visit 1 of the protocol.
Study NCT06333340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patient is given oxytocin 5 IU diluted in 10 mL normal saline, administered intravenously over 1 min, followed by continuous infusion of 250 mIU/min over 4 hours.
Study NCT06333340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient is given carbetocin 100 mcg diluted in 10 mL normal saline, administered intravenously over 1 min, followed by placebo infusion for 4 hours.
Study NCT04491981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Encapsulated Glass Ionomer Cement
Description: Repair of restorations in primary molars using Encapsulated High Viscosity Glass Ionomer (RIVA Self Cure - SDI). No local anesthesia will be used. A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with GIC (Glass Ionomer Cement).
Study NCT04491981 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Composite resin
Description: Repair of restorations in primary molars using composite resin (Filtek Bulk Fill- 3M ESPE.) No local anesthesia will be used.A portion of the former restoration and infected carious tissue can be removed if necessary, and then the restoration will be repaired with CR (composite resin).
Study NCT06185439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prenatal Pilates Assisted Childbirth Preparation Training
Description: Training was given twice a week for two hours a day (one hour of theory, one An hour of exercise = 45 minutes of pregnant plates and 15 minutes of breathing exercises) total eight weeks.
Study NCT05161845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps and Rubella Combined Vaccine, Live
Description: 0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.
Study NCT03526991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator (SCS)
Description: The SCS implantation technique consists of inserting epidural leads-containing multiple stimulating electrodes (8). Two leads will be implanted percutaneously into the epidural space.~The implantable pulse generator (IPG) is a neurostimulation system designed to deliver low-intensity electrical impulses. The system is intended to be used with leads and extensions that are compatible with the system. This neurostimulation system is indicated (FDA approved) as an aid in the management of chronic, intractable pain of the trunk and/or limbs. The intended use in this study is considered experimental.
Study NCT05122689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate
Description: Dietary inorganic nitrate (0,12 mmol sodium-nitrate/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
Study NCT05122689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Dietary sodium-chloride (0,12 mmol sodium-chloride/kg BW/day) dissolved in 200 ml tap water. Supplementation for 30 days.
Study NCT06087497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early mobilization
Description: Z stitch placement is standard of care to achieve vascular hemostasis after EP procedures which is followed by 4 hours of bedrest. In this study, we will compare patient satisfaction and bleeding complications with a shorter bedrest (1 hour instead of 4 hours)
Study NCT04953741 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate inhaled aerosol
Description: The study consists of two stages and include three groups. Three groups include: Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped Fluticasone propionate Inhaled Aerosol and continuation of montelukast once a day; Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day and continuation of montelukast once a day，and then stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug once a day; Stopped montelukast and continuation of Fluticasone propionate Inhaled Aerosol 125 ug twice daily, and then Reduced dose Fluticasone propionate Inhaled Aerosol 125 ug once a day. The scheme of every group is divided into two stages. Only those whose asthma are well controlled at the end of the first phase will be allowed to proceed to the next phase.
Study NCT04709497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: viscotrabeculotomy (VT)
Description: viscotrabeculotomy (VT)
Study NCT04709497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: visco-circumferential-suture-trabeculotomy (VCST) .
Description: visco-circumferential-suture-trabeculotomy (VCST)
Study NCT04709497 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined VT-Trabeculectomy with MMC (VT-Trab).
Description: combined VT-Trabeculectomy with MMC (VT-Trab).
Study NCT06002659 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR20(NAP)-T
Description: Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP
Study NCT06002659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: pre-conditioning chemotherapy
Study NCT06002659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: pre-conditioning chemotherapy
Study NCT05265832 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Description: Endocapsular technique (Divide-and-conquer) and supracapsular technique (Subluxation) will be used equally.
Study NCT05863234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPMX-T003
Description: The therapeutic agent is administered continuously intravenously
Study NCT05169580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pociredir oral capsule(s)
Description: Participants will receive Pociredir
Study NCT05155319 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UFluA 20 µg each antigen/dose
Description: Low dose
Study NCT05155319 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: UFluA 60 µg each antigen/dose
Description: High Dose
Study NCT05155319 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05155319 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05218174 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
Study NCT05218174 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise Prescription
Description: In this prospective, randomized control trial, the investigators will compare functional exercise capacity, cognitive performance, and emotional well-being at baseline and following 2 conditions: (1) an 8-week exercise training program (intervention) or (2) no training program (control). Participants will be randomized using a 1:1 randomization scheme into either the intervention or control group. After 8 weeks, participants in the wait-list control group will begin the intervention for the next 8 weeks and activity undergone by participants first randomized into the intervention group will remain under observation.
Study NCT06030388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: Both interventions (strength training and high intensity aerobic training) will be introduced with a 3-week adaptation period with lower loads (strength training) or intensity (aerobic training) followed by a 12-week period on the intended load/intensity. All participants in the intervention groups will be recommended to exercise three times per week (one hour per session) and in addition be active with everyday low-intensity physical activity. A structured and detailed training diary will be used in both groups to register frequency of each training session, as well as everyday physical activity. For the strength training, load and dose will also be registered for each training session.